Elevar Therapeutics announced that data from the ANGEL trial has been accepted for a podium presentation by the European Society for Professional Oncology at the annual meeting in Barcelona, Spain. The ANGEL trial is a randomized phase 3 study of Rivoceranib (commonly known as Apatinib) plus best supportive care in gastric cancer patients who had failed at least 2 prior lines of therapy. This presentation will be the first public disclosure of ANGEL study data since the announcement of the topline results in June.
“The ANGEL study represents the first large study of Rivoceranib in a global patient population,” said Steven Norton PhD, MBA, Vice President Clinical Development at Elevar Therapeutics. “We appreciate the opportunity for Rivoceranib data to be presented at ESMO 2019 and to be able to gather insights from leading oncologists globally during the conference.”
ANGEL Trial Podium Presentation at ESMO
September 29, 2019 at 11:00 am CET
Randomized phase 3 ANGEL study of Rivoceranib (Apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed 2 prior chemotherapy regimens (ID 4088)
Location: Fira Barcelona Convention Centre, Madrid Auditorium (Hall 2)
Yoon-Koo Kang, MD, PhD, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Medical Degree: Seoul National University and PhD: Seoul National University. Before joining the Asan Medical Center, Dr. Kang finished a research fellowship at the National Cancer Institute at NIH, USA and led the clinical program of hematology/oncology and the Laboratory of Experimental Therapeutics at the Korea Cancer Center Hospital in Seoul. Min-Hee Ryu, MD, University of Ulsan Master of Medicine: Seoul National University Bachelor of Medicine: Seoul National University Major Professional Experiences Associate Professor in Oncology, UUCM AMC Assistant Professor in Oncology, UUCM AMC Fellowship in HematoOncology, UUCM AMC Residency in Seoul National University Hospital Internship in Seoul National University Hospital ESMO is a leading professional organization for medical oncology, with over 20,000 members from over 150 countries worldwide. Elevar Therapeutics will be exhibiting at booth #229 during the exhibit hours from September 27-30 at the Fira Barcelona Convention Centre, Hall 3. Source: Elevar Therapeutics Website